Daniel Fowler
Company: Rapa Therapeutics
Job title: Chief Medical Officer
Seminars:
Clinical Translation of Hybrid Treg/Th2 (RAPA501) Cells for Therapy of ALS 2:30 pm
Mechanism of action of RAPA501 Phase 1 results; manufacturing, safety and immune modulation Implementing 40 patient Expanded Access trial (<50% pulmonary function) Implementing Phase 2/3 trial (>70% pulmonary function)Read more
day: Conference Day One Track B PM